Theoretically, agents simultaneously blocking TGF-β and PD-1/PD-L1 pathways might have superior anti-tumor activity, relative to anti-PD-1/PD-L1 monoclonal antibodies. This evidence concerns the gene TGFB1 and neoplasm.